REFERENCES
- Huang C, Wang Y, Li X, et al. Clinical features of patients infected
with 2019 novel coronavirus in Wuhan, China. Lancet .
2020;395:497-506.
- Anca PS, Toth P P, Kempler P, Rizzo M. Gender differences in the
battle against COVID‐19: Impact of genetics, comorbidities,
inflammation and lifestyle on differences in outcomes. Int J
Clin Pract. 2021;75 (2):e13666.
- Kamboj M, Sepkowitz KA. Nosocomial infections in patients with cancer.Lancet Oncol . 2009;10:589-597.
- Rüthrich MM, Giessen-Jung C, Borgmann S, et al. COVID-19 in cancer
patients: clinical characteristics and outcome-an analysis of the
LEOSS registry. Ann Hematol . 2021;100:383-393.
- Liu H, Chen S, Liu M, Nie H, Lu H. Comorbid chronic diseases are
strongly correlated with disease severity among COVID-19 patients: a
systematic review and meta-analysis. Aging Dis .
2020;11:668-678.
- Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2
infection: a nationwide analysis in China. Lancet Oncol .
2020;21:335-337.
- Guan WJ, Ni ZY, Hu Y, et al. Clinical characteristics of coronavirus
disease 2019 in China. N Engl J Med . 2020;382:1708-1720.
- Lacey B, Lewington S, Clarke R, et al. Age-specific association
between blood pressure and vascular and non-vascular chronic diseases
in 0· 5 million adults in China: a prospective cohort study.Lancet Glob Health . 2018;6:e641-e649.
- Oruç MA, Öz H, Öztürk O. Investigation of the disease process and drug
combinations in patients with suspected/confirmed COVID‐19 using
favipiravir. Int j Clin Pract . 2021;00:e14167.
- Yang J, Zheng YA, Gou X, et al. Prevalence of comorbidities and its
effects in patients infected with SARS-CoV-2: a systematic review and
meta-analysis. Int J Infect Dis . 2020;94:91-95.
- Frater JL, Zini G, d’Onofrio G, Rogers HJ. COVID‐19 and the clinical
hematology laboratory. Int J Lab Hematol . 2020;42:11-18.
- Liu F, Li L, Xu M, et al. Prognostic value of interleukin-6,
C-reactive protein, and procalcitonin in patients with COVID-19.J Clin Virol . 2020;127:104370.
- Wang, L. C-reactive protein levels in the early stage of COVID-19.Med Mal Infect . 2020;50:332-334.
- Zhang L, Yan X, Fan Q, et al. D‐dimer levels on admission to predict
in‐hospital mortality in patients with Covid‐19. J Thromb
Haemost . 2020;18:1324-1329.
- Liu J, Liu Y, Xiang P, et al. Neutrophil-to-lymphocyte ratio predicts
critical illness patients with 2019 coronavirus disease in the early
stage. J Transl Med . 2020;18:1-12.
- Azab B, Zaher M, Weiserbs KF, et al. Usefulness of neutrophil to
lymphocyte ratio in predicting short-and long-term mortality after
non–ST-elevation myocardial infarction. Am J Cardiol .
2010;106:470-476.
- Guthrie GJ, Charles KA, Roxburgh CS, Horgan PG, McMillan DC, Clarke
SJ. (2013). The systemic inflammation-based neutrophil–lymphocyte
ratio: experience in patients with cancer. Crit Rev Oncol
Hematol . 2013;88:218-230.
- Giede-Jeppe A, Bobinger T, Gerner ST, et al. Neutrophil-to-lymphocyte
ratio is an independent predictor for in-hospital mortality in
spontaneous intracerebral hemorrhage. Cerebrovasc Dis .
2017;44:26-34.
- Liu Y, Du X, Chen J, et al. Neutrophil-to-lymphocyte ratio as an
independent risk factor for mortality in hospitalized patients with
COVID-19. J Infect . 2020;81:e6-e12.
- Qin C, Zhou L, Hu Z, et al. Dysregulation of immune response in
patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin
Infect Dis . 2020;71:762-768.
- Liu H, Chen S, Liu M, Nie H, Lu H. Comorbid chronic diseases are
strongly correlated with disease severity among COVID-19 patients: a
systematic review and meta-analysis. Aging Dis .
2020;11:668-678.
- Yang F, Shi S, Zhu J, Shi J, Dai K, Chen X. (2020). Clinical
characteristics and outcomes of cancer patients with COVID‐19. J
Med Virol . 2020;92:2067-2073.
- Liang W, Guan W, Chen R, et al. Cancer patients in SARS-CoV-2
infection: a nationwide analysis in China. Lancet Oncol .
2020;21:335-337.
- Bellan M, Patti G, Hayden E, et al. Fatality rate and predictors of
mortality in an Italian cohort of hospitalized COVID-19
patients. Sci Rep . 2020;10:1-10.
- Stroppa EM, Toscani I, Citterio C, et al. Coronavirus disease-2019 in
cancer patients. A report of the first 25 cancer patients in a western
country (Italy). Future Oncol . 2020;16:1425-1432.
- Taneri PE, Gómez-Ochoa SA, Llanaj E, et al. Anemia and iron metabolism
in COVID-19: a systematic review and meta-analysis. Eur J
Epidemiol . 2020;35:763-773.
- Gómez-Pastora J, Weigand M, Kim J, et al. Hyperferritinemia in
critically ill COVID-19 patients–Is ferritin the product of
inflammation or a pathogenic mediator?. Clin Chim Acta .
2020;509:249-251.
- Shoenfeld Y. Corona (COVID-19) time musings: our involvement in
COVID-19 pathogenesis, diagnosis, treatment and vaccine planning.Autoimmun Rev . 2020;19:102538.
TABLE 1 Some demographic characteristics of the patients and their
distribution based on chronic systemic disease status